Volume 48, Number 8, 1560-1564, DOI: 10.1007/s00125-005-1829-9

Published in partnership with the

Logo

European Association for the Study of Diabetes

Pancreatic beta and alpha cells are both decreased in patients with fulminant type 1 diabetes: a morphometrical assessment

K. Sayama, A. Imagawa, K. Okita, S. Uno, M. Moriwaki, J. Kozawa, H. Iwahashi, K. Yamagata, S. Tamura and Y. Matsuzawa, et al.

View Related Documents

Abstract

Aims/hypothesis  

We have previously reported that fulminant type 1 diabetes is characterised by an absence of diabetes-related antibodies and a remarkably abrupt onset. However, little is known about the mechanism of beta cell destruction in this diabetes subtype, and to obtain insights into the aetiology of the disease, we investigated residual endocrine cells and the expression of Fas and Fas ligand in fulminant type 1 diabetes.

Methods  

Residual beta and alpha cells were morphologically assessed in pancreatic tissue obtained by biopsy from five patients with recent-onset fulminant type 1 diabetes and five patients with recent-onset typical autoimmune type 1 diabetes. In addition, the expression of Fas and Fas ligand was evaluated by immunohistochemistry.

Results  

In fulminant type 1 diabetes, beta and alpha cell areas were decreased significantly, compared with autoimmune type 1 diabetes and control subjects. In contrast, the alpha cell area was not decreased significantly in autoimmune type 1 diabetes, compared with that in control subjects. No Fas expression in islets and Fas ligand expression in CD3+ cells in the exocrine pancreas were found in the fulminant type 1 diabetic patients who underwent this evaluation.

Conclusions/interpretation  

Our study showed that beta and alpha cells are damaged in fulminant type 1 diabetes. In addition to the lack of Fas and Fas ligand expression, the results suggest that the mechanism of beta cell destruction in fulminant type 1 diabetes is different from that in autoimmune type 1 diabetes.

Keywords  Alpha cell - Biopsy - Fas - Fas ligand - Fulminant type 1 diabetes - Human - Immunohistochemistry - Morphometry - Type 1 diabetes

Fulltext Preview

Image of the first page of the fulltext document